Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...
The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after ...
Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...
The U.S. Food and Drug Administration has placed a hold on trials of Novavax's COVID and influenza combination vaccine, as ...
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...
Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax’s Investigational New Drug ...
Novavax’s plans for growth outside of its COVID program have been thrown into chaos after the FDA put the biooharma's flu ...
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...
The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu ...
On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.